Pomegranate juice supplementation in chronic obstructive pulmonary disease:: a 5-week randomized, double-blind, placebo-controlled trial
Pomegranate juice supplementation in chronic obstructive pulmonary disease:: a 5-week randomized, double-blind, placebo-controlled trial
复制标题
DOI：
10.1038/sj.ejcn.1602309
复制
发表时间：
2006-02-01
影响因子：
4.7
通讯作者：
Espín, JC
中科院分区：
文献类型：
--
作者：
Cerdá, B;Soto, C;Espín, JC
目的：本研究的目的是调查抗氧化剂多酚丰富的石榴汁（PJ）补充5周对稳定的慢性阻塞性肺疾病（COPD）患者的影响，因为氧化应激在COPD的演变和病理生理学中起着重要作用。设计：进行随机、双盲、安慰剂对照试验。共30例稳定期COPD患者随机分为两组（每组15例）。干预措施：两组每天饮用400 ml PJ或匹配的安慰剂（合成橙味饮料），持续5周。评估了PJ的Trolox等效抗氧化能力（TEAC）、血液参数（14项血液学参数和18项血清生物化学参数）、呼吸功能变量、PJ多酚（血浆和尿液）和尿异前列腺素（8-iso-PGF（2 α））的生物利用度。结果：PJ的每日剂量（含有2.66 g多酚）提供4 mmol/l TEAC。在志愿者的血浆或尿液中均未检测到PJ中存在的多酚。最丰富的PJ多酚，鞣花单宁，由COPD患者的结肠微生物区系代谢，在血浆和尿液中产生两种主要代谢物（二苯并吡喃酮衍生物），无TEAC。PJ和安慰剂组之间没有发现任何差异（P > 0.05）的参数评价（血清生化和血液学），尿8-异前列腺素F（2 α），呼吸功能变量和临床症状的COPD patients.Conclusions：我们的研究结果表明，PJ补充剂没有增加目前的标准治疗稳定的COPD患者的好处。PJ的高TEAC不能在体内外推，可能是由于其多酚类物质被结肠微生物群代谢。在声称任何与抗氧化剂相关的健康益处之前，了解膳食多酚的不同生物利用度至关重要。
Objective: The aim of the present study is to investigate the effect of antioxidant polyphenol-rich pomegranate juice (PJ) supplementation for 5 weeks on patients with stable chronic obstructive pulmonary disease (COPD), since the oxidative stress plays a major role in the evolution and pathophysiology of COPD.Design: A randomized, double-blind, placebo-controlled trial was conducted.Subjects: A total of 30 patients with stable COPD were randomly distributed in two groups (15 patients each).Interventions: Both groups consumed either 400 ml PJ daily or matched placebo (synthetic orange-flavoured drink) for 5 weeks. Trolox Equivalent Antioxidant Capacity (TEAC) of PJ, blood parameters (14 haematological and 18 serobiochemical), respiratory function variables, bioavailability of PJ polyphenols (plasma and urine) and urinary isoprostane (8-iso-PGF(2 alpha)) were evaluated.Results: The daily dose of PJ (containing 2.66 g polyphenols) provided 4 mmol/l TEAC. None of the polyphenols present in PJ were detected in plasma or in urine of volunteers. The most abundant PJ polyphenols, ellagitannins, were metabolized by the colonic microflora of COPD patients to yield two major metabolites in both plasma and urine (dibenzopyranone derivatives) with no TEAC. No differences were found (P > 0.05) between PJ and placebo groups for any of the parameters evaluated (serobiochemical and haematological), urinary 8-iso-PGF(2 alpha), respiratory function variables and clinical symptoms of COPD patients.Conclusions: Our results suggest that PJ supplementation adds no benefit to the current standard therapy in patients with stable COPD. The high TEAC of PJ cannot be extrapolated in vivo probably due to the metabolism of its polyphenols by the colonic microflora. The understanding of the different bioavailability of dietary polyphenols is critical before claiming any antioxidant-related health benefit.